<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Venous thromboembolism in pregnancy and postpartum: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Venous thromboembolism in pregnancy and postpartum: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Venous thromboembolism in pregnancy and postpartum: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Atul Malhotra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Weinberger, MD, MACP, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James D Douketis, MD, FRCPC, FACP, FCCP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lower extremity deep vein thrombosis (DVT) and pulmonary embolism (PE) are collectively referred to as venous thromboembolism (VTE). Pregnancy and the postpartum period are well-established risk factors for VTE.</p><p>This topic will discuss treatment options for VTE in pregnant and postpartum patients, which differ from those associated with treatment of nonpregnant patients in several ways [<a href="#rid1">1-6</a>]. The suggestions in this topic are based on the assumption that a radiologic diagnosis of DVT and/or PE has been made. Our approach is generally consistent with the guidelines on management of VTE in pregnancy published by the American College of Chest Physicians (ACCP), American College of Obstetricians and Gynecologists (ACOG), European Society of Cardiology (ESC), European Respiratory Society (ERS), and American Society of Hematology (ASH) [<a href="#rid1">1,7-10</a>].</p><p>The epidemiology, pathogenesis, diagnosis, and prevention of VTE during pregnancy and the postpartum period are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1349.html" rel="external">"Deep vein thrombosis in pregnancy: Epidemiology, pathogenesis, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89374.html" rel="external">"Pulmonary embolism in pregnancy: Clinical presentation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a>.)</p><p></p><p>Other VTE-related issues in nonpregnant individuals are also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p></p><p class="headingAnchor" id="H2637592484"><span class="h1">GENERAL PRINCIPLES OF TREATMENT</span><span class="headingEndMark"> — </span>We endorse a multidisciplinary approach using similar indications as in the nonpregnant population.</p><p class="headingAnchor" id="H2"><span class="h2">Indications</span><span class="headingEndMark"> — </span>We consider the following approach as reasonable during pregnancy and the postpartum period:</p><p class="headingAnchor" id="H3772409691"><span class="h3">Proximal DVT and symptomatic PE</span><span class="headingEndMark"> — </span>Indications for treating pregnant and postpartum patients with proximal DVT and/or symptomatic PE are generally similar to the nonpregnant population  (<a class="graphic graphic_algorithm graphicRef131964" href="/d/graphic/131964.html" rel="external">algorithm 1</a>), the details of which are found separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Indications'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H1706359411"><span class="h3">Distal DVT and small subsegmental PE</span><span class="headingEndMark"> — </span>During pregnancy, the optimal treatment of distal DVT (ie, calf vein DVT) and incidental or small subsegmental PE (SSPE) is unknown. Our approach for most patients with distal DVT or SSPE is treatment with anticoagulation, although there may be rare exceptions (eg, very small perforator vein clot and normal D-dimer level, suspected artifact on computed tomographic pulmonary angiography). Further details regarding indications for management of distal DVT and SSPE in nonpregnant patients are provided separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Distal DVT'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Patients with subsegmental PE'</a>.)</p><p class="headingAnchor" id="H2347903142"><span class="h3">Empiric therapy</span><span class="headingEndMark"> — </span>Principles of empiric therapy are similar to those in nonpregnant individuals. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'Empiric anticoagulation'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Empiric anticoagulation'</a>.)</p><p class="headingAnchor" id="H2303347700"><span class="h2">Multidisciplinary team</span><span class="headingEndMark"> — </span>When managing patients with venous thromboembolism (VTE) during pregnancy and the postpartum period, we advocate for a multidisciplinary approach (eg, PE response team, pulmonology, maternal-fetal medicine, obstetric anesthesia, hematology, neonatology). This is particularly important for those with complex VTE or life-threatening symptoms, in whom the choice of treatment is influenced by specific clinical factors, such as stage of pregnancy and proximity to delivery. The value of multidisciplinary teams in the management of life-threatening PE in nonpregnant individuals is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Pulmonary embolism response teams (PERT)'</a>.)</p><p class="headingAnchor" id="H1050963742"><span class="h1">NON-LIFE-THREATENING THROMBOSIS</span></p><p class="headingAnchor" id="H3715602065"><span class="h2">Assess bleeding risk</span><span class="headingEndMark"> — </span>Since anticoagulation is the cornerstone of therapy, we assess the bleeding risk in all patients who develop venous thromboembolism (VTE) during pregnancy or the postpartum period. The de novo risk of bleeding in most pregnant patients is low. However, the consequences associated with bleeding in patients who develop specific obstetric complications can lead to potentially devastating outcomes, thereby increasing this risk for pregnant patients in general.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General bleeding risk</strong> – As with nonpregnant patients, we categorize pregnant individuals as low risk (ie, three-month bleeding risk &lt;2 percent) or high-risk (ie, bleeding risk &gt;13 percent) based on a number of risk factors (eg, age, platelet count, comorbidities)  (<a class="graphic graphic_table graphicRef97160" href="/d/graphic/97160.html" rel="external">table 1</a>). For patients with a bleeding risk between these values (moderate risk), the optimal management must be individualized according to the values and preferences of the patient as well as the risk-benefit ratio, which may change over time. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Assessing bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Risk of bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstetric-specific risk</strong> – Unique to pregnancy are the risks of antepartum placental abruption (with both consumptive and dilutional disseminated coagulopathy) and postpartum hemorrhage, both of which can have catastrophic consequences (eg, maternal disseminated intravascular coagulation, hypovolemic shock, death; fetal distress, fetal growth restriction, fetal and neonatal death). The frequency of these outcomes as a result of therapeutic anticoagulation is poorly quantified. Risk factors and consequences for these conditions are discussed separately. (See  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/d/html/6710.html" rel="external">"Overview of postpartum hemorrhage"</a>.)</p><p></p><p class="headingAnchor" id="H585043162"><span class="h2">Most patients: Anticoagulation</span><span class="headingEndMark"> — </span>Similar to nonpregnant patients, anticoagulation is the mainstay of therapy for VTE in pregnant and postpartum patients, provided there is no contraindication. However, agent selection and duration of anticoagulant therapy differs from the nonpregnant population [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H757714325"><span class="h3">During pregnancy, labor and delivery, and postpartum</span><span class="headingEndMark"> — </span>Anticoagulation differs between the different stages of pregnancy and the postpartum period.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>During pregnancy</strong> – Agent choice and efficacy data that support anticoagulants in pregnant patients with VTE are similar to pregnant patients with other indications for anticoagulant therapy  (<a class="graphic graphic_table graphicRef140440" href="/d/graphic/140440.html" rel="external">table 2</a>).</p><p class="bulletIndent1">In brief, the following applies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most pregnant patients, subcutaneous low molecular weight (LMW) heparin is the agent of choice  (<a class="graphic graphic_table graphicRef140440" href="/d/graphic/140440.html" rel="external">table 2</a>). LMW heparin may be switched to <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> (UFH) in some patients prior to labor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and direct oral anticoagulants (DOACs) are typically avoided in pregnancy.</p><p></p><p class="bulletIndent1">The rationale for agent choice as well as suitable agents for patients with acute renal failure, patients who need rapid short-term control of anticoagulation, and alternatives to heparin are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Choice of anticoagulant'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Labor and delivery</strong> – We generally avoid anticoagulation during labor and delivery. In rare cases of VTE, when even a short interval without anticoagulant therapy is undesirable (eg, hemodynamically significant PE within previous two to four weeks, poor cardiopulmonary reserve), either delivery can proceed despite full anticoagulation or a temporary inferior vena cava (IVC) filter can be inserted and anticoagulation discontinued [<a href="#rid11">11</a>]. Choosing among these options should be decided on a case-by-case basis with a multidisciplinary team approach and shared decision making with the patient. Management of anticoagulation during labor and delivery and role of an IVC filter are provided separately. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Labor and delivery'</a> and <a class="local">'IVC filter predelivery'</a> below.)</p><p></p><p class="bulletIndent1">If labor begins unexpectedly, delivery on full anticoagulation is feasible; many patients who deliver while anticoagulated do not have excessive intrapartum bleeding or require a reversal agent [<a href="#rid11">11</a>]. However, neuraxial anesthesia should not be administered to such patients due to the risk of spinal or epidural hematoma [<a href="#rid12">12,13</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Neuraxial anesthesia'</a> and  <a class="medical medical_review" href="/d/html/4469.html" rel="external">"Adverse effects of neuraxial analgesia and anesthesia for obstetrics", section on 'Neuraxial analgesia and the anticoagulated patient'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum and lactation</strong> – Agent choice in the postpartum period depends on patient preferences, desire for lactation, complications that may have occurred during labor and delivery (eg, postpartum hemorrhage, traumatic neuraxial catheter placement) or complications that may require further intervention (eg, potential dilation and curettage for retained placental products).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients in whom lactation is desired and no procedure is anticipated, LMW heparin is our <strong>initial</strong> agent of choice after delivery. We continue LMW heparin through the postpartum period or transition to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> if desired by the patient. For patients in whom a potential procedure is anticipated, intravenous UFH is the usual alternative. DOACs are avoided during breast feeding [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients in whom lactation is not desired, LMW heparin, UFH, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, or a DOAC is appropriate. Our preference is to use a DOAC, although data to support DOACs in this setting are indirect and derived from the nonpregnant population. (See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Anticoagulation in postpartum patients and those who are lactating is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Postpartum and breastfeeding'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>For patients with VTE during pregnancy or the postpartum period, the optimal duration of anticoagulation is unknown and should be individualized on a case-by-case basis.</p><p></p><p>Our approach is based on extrapolated data from the nonpregnant population, the known high risk of VTE during pregnancy and the first six weeks postpartum, as well as our clinical experience [<a href="#rid1">1,15-18</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>For those with VTE diagnosed during pregnancy, we treat with anticoagulant therapy for <strong>at least</strong> three months; this duration should include the remainder of pregnancy and at least six weeks postpartum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with VTE diagnosed postpartum, we treat with anticoagulation for a minimum of three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once the finite period of anticoagulant therapy is completed, we evaluate patients for possible continued or indefinite therapy (eg, persistent risk factors). We follow the same general principles as in the nonpregnant population. (See  <a class="medical medical_review" href="/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="headingAnchor" id="H162511943"><span class="h3">Outpatient anticoagulation</span><span class="headingEndMark"> — </span>Some patients with VTE may have anticoagulant therapy initiated solely as an outpatient. Such patients must be carefully selected and meet the same selection criteria as nonpregnant patients. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'</a>.)</p><p>When outpatient anticoagulation therapy is selected, we typically use LMW heparin since DOACs are avoided during pregnancy and breastfeeding. (See <a class="local">'During pregnancy, labor and delivery, and postpartum'</a> above.)</p><p>Only limited data support outpatient therapy in pregnant patients. In one observational study including 126 patients with VTE, 16 of whom were treated as an outpatient, none had VTE recurrence or death [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H11267517"><span class="h3">IVC filter predelivery</span><span class="headingEndMark"> — </span>For pregnant patients with VTE who are at low bleeding risk, we do not routinely place an IVC filter. The vast majority of patients who need an IVC filter are those with contraindication to anticoagulation, the details of which are discussed below. (see <a class="local">'Patients at high bleeding risk or contraindications to anticoagulation: IVC filter'</a> below)</p><p>Infrequently, however, we sometimes concurrently place an IVC filter when the pulmonary vascular bed is already significantly compromised and unlikely to tolerate another insult (eg, large PE, chronic thromboembolic pulmonary hypertension, significant underlying lung disease) or when bleeding is anticipated and the risk of stopping anticoagulation, even for a short period, is undesirable (eg, hemodynamically significant PE within previous two to four weeks). (See <a class="local">'During pregnancy, labor and delivery, and postpartum'</a> above and <a class="local">'Patients at high bleeding risk or contraindications to anticoagulation: IVC filter'</a> below.)</p><p class="headingAnchor" id="H973490804"><span class="h2">Patients at high bleeding risk or contraindications to anticoagulation: IVC filter</span><span class="headingEndMark"> — </span>Similar to the nonpregnant population, for those in whom anticoagulation is contraindicated or the bleeding risk is too high for the administration of anticoagulant therapy, options are limited to the placement of an IVC filter. For such patients, we place a suprarenal, temporary, retrievable IVC filter since pregnant and postpartum patients tend to be young and have transient risk factors for VTE (eg, pregnancy, cesarean birth) [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at high risk of bleeding'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Inferior vena cava filter'</a>.)</p><p>As IVC filters are generally inserted under fluoroscopy, we discuss with patients the potential risks of radiation to the fetus as well as to the mother [<a href="#rid22">22-24</a>]; use of iodinated contrast during pregnancy does not appear to pose any risk to the fetus. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Use of iodinated contrast materials'</a>.)</p><p>Studies evaluating the risks of fluoroscopy in pregnancy are limited. In one study using software calculations and model patients to evaluate radiation dose during IVC placement in pregnancy, total radiation dose to the fetus averaged approximately 2 milligray (mGy); cumulative radiation doses were slightly lower at later gestations compared with earlier gestations because part of the fetus was outside of the radiation field [<a href="#rid22">22</a>]. This is considerably lower than 50 mGy, which is the threshold at which adverse effects of radiation effects may be observed [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Dose threshold'</a>.)</p><p>IVC filters placed during pregnancy also appear to be well tolerated, but data are limited [<a href="#rid23">23,27-31</a>]. In one review including 199 patients in whom an IVC filter was inserted during pregnancy, the risks of filter complications were comparable with the nonpregnant population [<a href="#rid27">27</a>]. However, inability to later retrieve a filter placed during the third trimester of pregnancy has been reported due to filter tilt, a feature that may be due to anatomical alterations in positioning during pregnancy or labor and delivery [<a href="#rid31">31</a>].</p><p>The insertion and complication of IVC filters are discussed separately. (See  <a class="medical medical_review" href="/d/html/8212.html" rel="external">"Placement of vena cava filters and their complications"</a>.)</p><p class="headingAnchor" id="H334341518"><span class="h1">PATIENTS WITH LIFE-THREATENING THROMBOSIS</span><span class="headingEndMark"> — </span>During pregnancy and the postpartum period, life-threatening venous thromboembolism (VTE) symptoms are mostly due to hemodynamically unstable PE. Less commonly, limb- and life-threatening symptoms are due to extensive proximal or iliofemoral DVT (eg, phlegmasia cerulea dolens). (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism", section on 'Hemodynamically unstable patients'</a> and  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'History'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Thrombolysis/thrombectomy</span><span class="headingEndMark"> — </span>Similar to the nonpregnant population, the approach to management varies depending on the risk of bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most patients with life-threatening symptoms: Thrombolysis</strong> – For pregnant patients who present with life-threatening symptoms due to VTE, we evaluate for thrombolysis  (<a class="graphic graphic_table graphicRef82171" href="/d/graphic/82171.html" rel="external">table 3</a>), typically with tissue plasminogen activator (systemic or catheter-directed for PE, catheter-directed for DVT). The principles of the evaluation are the same as for nonpregnant patients, although the risk-benefit ratio is altered due to the added potential of maternal, placental, or fetal hemorrhage. This evaluation is provided separately. (See  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"</a> and  <a class="medical medical_review" href="/d/html/121197.html" rel="external">"Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"</a>.)</p><p></p><p class="bulletIndent1">For life-threatening PE in nonpregnant patients, systemic thrombolysis is usually performed since it is universally available. However, in centers with available expertise and equipment, catheter-directed techniques may be preferred due to the likely reduction in the risk of major bleeding and ability by some techniques to perform mechanical thrombus extraction, although supportive data in pregnant patients are lacking. A PE response team can facilitate this decision. Limb- and life-threatening symptoms due to DVT are almost invariably performed using catheter-directed techniques. (See  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Catheter-directed approaches'</a> and  <a class="medical medical_review" href="/d/html/121197.html" rel="external">"Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration", section on 'Route of administration (catheter-directed)'</a>.)</p><p></p><p class="bulletIndent1">While pregnancy is listed as a <strong>relative</strong> contraindication to thrombolysis  (<a class="graphic graphic_table graphicRef95035" href="/d/graphic/95035.html" rel="external">table 4</a>), case reports and anecdotal evidence suggest successful use when reserved for life-threatening symptoms [<a href="#rid32">32-40</a>]. In a systematic review of case series including 83 pregnant patients with severe PE treated with thrombolytic therapy (mostly systemic <a class="drug drug_general" data-topicid="8478" href="/d/drug information/8478.html" rel="external">alteplase</a>), outcomes were as follows: maternal survival (94 percent), major bleeding postpartum (58 percent), major bleeding antepartum (17 percent), and fetal loss (possible related to PE or its treatment; 12 percent) [<a href="#rid38">38</a>]. In a subsequent meta-analysis including 141 pregnant patients who underwent thrombolysis, outcomes included: maternal death (2.8 percent), major bleeding (8.5 percent), fetal death (1.4 percent), miscarriage (6.4 percent), and preterm delivery (9.9 percent) [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">Teratogenicity due to thrombolytic agents has not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients in whom thrombolysis is not feasible: Thrombectomy</strong> – Surgical or catheter-directed thrombectomy may be the only option when thrombolytic therapy cannot be performed (eg, patients decline, bleeding risk is high, or thrombolysis is absolutely contraindicated  (<a class="graphic graphic_table graphicRef95035" href="/d/graphic/95035.html" rel="external">table 4</a>)) or when thrombolysis fails.</p><p></p><p class="bulletIndent1">Case reports of thrombectomy during pregnancy suggest that it can be used successfully as a life-saving measure, especially if thrombolysis fails [<a href="#rid34">34,36,38</a>]. In the systematic review of case series discussed above, 36 patients with severe PE were treated with thrombectomy; outcomes for the 36 patients treated with thrombectomy included: survival (86 percent), major bleeding (20 percent), and fetal death (possibly related to surgery; 20 percent) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1">Factors that influence the decision to proceed with surgical thrombectomy are discussed separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Embolectomy'</a> and  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration", section on 'Failure to improve or deterioration despite anticoagulation'</a> and  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Thrombolytic therapy and thrombectomy'</a> and  <a class="medical medical_review" href="/d/html/121197.html" rel="external">"Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration", section on 'Patients at high risk of bleeding or contraindications to thrombolysis'</a> and  <a class="medical medical_review" href="/d/html/121197.html" rel="external">"Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration", section on 'Poor functional status, limited life expectancy, DVT &gt;14 days'</a>.)</p><p></p><p class="headingAnchor" id="H4096419150"><span class="h2">Extracorporeal membrane oxygenation</span><span class="headingEndMark"> — </span>In life-threatening cases, extracorporeal membrane oxygenation (ECMO), typically venoarterial ECMO, may be needed. ECMO can temporarily stabilize and oxygenate the patient while therapy is ongoing or act as a bridge to definitive therapy (eg, hemodynamic support during severe amniotic fluid embolism, cardiac arrest, or massive PE).</p><p>ECMO-related outcomes during pregnancy are mostly extrapolated from patients who undergo ECMO for acute respiratory distress syndrome, as data are limited in pregnant females with PE [<a href="#rid38">38,41,42</a>]. In one systematic review, among the 21 patients with high-risk PE treated with ECMO that was often combined with other therapies, maternal survival was 76 percent, fetal survival was 63 percent, and the rate of major bleeding was 55 percent [<a href="#rid42">42</a>].</p><p>The value of ECMO in nonpregnant patients with PE and other conditions is provided separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Extracorporeal membrane oxygenation'</a> and  <a class="medical medical_review" href="/d/html/134279.html" rel="external">"Extracorporeal life support in adults: Management of venoarterial extracorporeal membrane oxygenation (V-A ECMO)"</a>.)</p><p class="headingAnchor" id="H1468941119"><span class="h1">THERAPIES OF UNCLEAR SIGNIFICANCE</span></p><p class="headingAnchor" id="H537941548"><span class="h2">Inferior vena cava filter predelivery</span><span class="headingEndMark"> — </span>While not our routine practice, sometimes a temporary, retrievable inferior vena cava filter is placed in patients predelivery, which is discussed above. (See <a class="local">'During pregnancy, labor and delivery, and postpartum'</a> above and <a class="local">'Patients at high bleeding risk or contraindications to anticoagulation: IVC filter'</a> above.)</p><p class="headingAnchor" id="H663436444"><span class="h2">Planned delivery</span><span class="headingEndMark"> — </span>For patients who have had high-risk PE or DVT during pregnancy, whether an induction of labor or cesarean birth is advisable is unknown. Typically, we wait for spontaneous vaginal delivery and only plan delivery using the typical indications. Multidisciplinary input may be useful in this regard. (See  <a class="medical medical_review" href="/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation"</a>.)</p><p class="headingAnchor" id="H575168389"><span class="h1">RECURRENT VENOUS THROMBOEMBOLISM ON ANTICOAGULATION</span><span class="headingEndMark"> — </span>For patients who develop recurrent venous thromboembolism while on anticoagulation, evaluation and management are similar to that in the nonpregnant population and depend on the etiology for recurrence (eg, subtherapeutic anticoagulation, suboptimal therapy, ongoing prothrombotic stimuli). This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Management of recurrence on therapy'</a>.)</p><p class="headingAnchor" id="H3530820567"><span class="h1">MONITORING AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Monitoring for complications of both VTE (eg, thrombus extension, recurrence) and anticoagulation (eg, bleeding, thrombocytopenia) is similar to nonpregnant patients. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Monitoring and follow-up'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Monitoring and follow-up'</a>.)</p><p>Testing of patients with VTE in pregnancy for an inherited thrombophilia is controversial and is also discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Selection of patients for testing'</a> and  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'When to test'</a>.)</p><p class="headingAnchor" id="H3092647430"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113663.html" rel="external">"Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117610.html" rel="external">"Society guideline links: Anticoagulation in pregnancy"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidisciplinary approach</strong> – Pregnancy and the postpartum period are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolism (VTE). Since treatment differs from that in nonpregnant patients in several ways, we advocate for a multidisciplinary approach (eg, PE response team, pulmonology, maternal-fetal medicine, obstetric anesthesia, hematology, neonatology). (See <a class="local">'Introduction'</a> above and <a class="local">'Multidisciplinary team'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most patients</strong> – Anticoagulant therapy is the cornerstone of treatment. (See <a class="local">'Indications'</a> above and <a class="local">'Most patients: Anticoagulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We assess the bleeding risk in all patients. The de novo risk of bleeding in most pregnant patients is low. However, the consequences associated with bleeding in patients who develop specific obstetric complications such as placental abruption and postpartum hemorrhage can lead to potentially devastating outcomes, thereby increasing this risk for pregnant patients in general. (See <a class="local">'Assess bleeding risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In most pregnant patients with VTE, subcutaneous low molecular weight (LMW) heparin is the agent of choice  (<a class="graphic graphic_table graphicRef140440" href="/d/graphic/140440.html" rel="external">table 2</a>); LMW heparin may be switched to <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> in some patients prior to labor. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> and direct oral anticoagulants are generally avoided in pregnancy. The rationale for LMW heparin, suitable agents for patients with acute renal failure or those who need rapid short-term control of anticoagulation, alternatives to heparin, and anticoagulant management during labor and delivery are discussed in detail elsewhere. (See <a class="local">'During pregnancy, labor and delivery, and postpartum'</a> above and  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some patients with VTE may have anticoagulant therapy initiated solely as an outpatient, typically LMW heparin. Such patients must be carefully selected and meet the same selection criteria as nonpregnant patients. These criteria are discussed separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Outpatient versus inpatient therapy'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Outpatient anticoagulation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most pregnant patients whose only risk factor for VTE was transient (eg, pregnancy, cesarean birth), we suggest that the total duration of anticoagulant therapy be <strong>at least</strong> three months (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For those with VTE during pregnancy this duration should include the remainder of pregnancy and at least six weeks postpartum. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at high bleeding risk or with contraindications to anticoagulation</strong> – For those in whom the bleeding risk is high or anticoagulation is contraindicated, placement of an inferior vena cava (IVC) filter is indicated. Indications for insertion of an IVC filter are the same in pregnant and nonpregnant patients and are discussed separately. (See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Patients at high risk of bleeding'</a> and  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Inferior vena cava filter'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with life-threatening thrombosis</strong> – In most cases of life-threatening thrombosis, we evaluate patients for thrombolysis; if the bleeding risk is high or patients fail thrombolysis, we evaluate for thrombectomy. The principles of the evaluation are the same as for nonpregnant patients, although the risk-benefit ratio is altered due to the increased and added potential for maternal, placental, or fetal hemorrhage. Further details on this evaluation are provided separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8259.html" rel="external">"Approach to thrombolytic (fibrinolytic) therapy in acute pulmonary embolism: Patient selection and administration"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/121197.html" rel="external">"Catheter-directed thrombolytic therapy in deep venous thrombosis of the lower extremity: Patient selection and administration"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Embolectomy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence and follow-up</strong> – The approach to recurrence and follow-up, including testing for inherited thrombophilias, is discussed in detail separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)", section on 'Monitoring and follow-up'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/8265.html" rel="external">"Treatment, prognosis, and follow-up of acute pulmonary embolism in adults", section on 'Monitoring and follow-up'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy", section on 'Selection of patients for testing'</a>.)</p><p></p><p class="headingAnchor" id="H387002466"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David R Schwartz, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.</a></li><li><a class="nounderline abstract_t">Marik PE, Plante LA. Venous thromboembolic disease and pregnancy. N Engl J Med 2008; 359:2025.</a></li><li><a class="nounderline abstract_t">Bourjeily G, Paidas M, Khalil H, et al. Pulmonary embolism in pregnancy. Lancet 2010; 375:500.</a></li><li><a class="nounderline abstract_t">Brown HL, Hiett AK. Deep vein thrombosis and pulmonary embolism in pregnancy: diagnosis, complications, and management. Clin Obstet Gynecol 2010; 53:345.</a></li><li><a class="nounderline abstract_t">Arya R. How I manage venous thromboembolism in pregnancy. Br J Haematol 2011; 153:698.</a></li><li><a class="nounderline abstract_t">Middeldorp S. How I treat pregnancy-related venous thromboembolism. Blood 2011; 118:5394.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. Thromboembolism in Pregnancy. ACOG 2018. ACOG Practice Bulletin 196.</a></li><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39:3165.</a></li><li><a class="nounderline abstract_t">Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2:3317.</a></li><li><a class="nounderline abstract_t">Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54.</a></li><li><a class="nounderline abstract_t">Dulitzki M, Pauzner R, Langevitz P, et al. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380.</a></li><li><a class="nounderline abstract_t">Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88:27A.</a></li><li><a class="nounderline abstract_t">Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338:1774.</a></li><li><a class="nounderline abstract_t">Cohen H, Arachchillage DR, Middeldorp S, et al. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14:1673.</a></li><li><a class="nounderline abstract_t">Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997; 24:499.</a></li><li><a class="nounderline abstract_t">Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67:519.</a></li><li><a class="nounderline abstract_t">Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332:1661.</a></li><li><a class="nounderline abstract_t">Kamel H, Navi BB, Sriram N, et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370:1307.</a></li><li><a class="nounderline abstract_t">Voke J, Keidan J, Pavord S, et al. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol 2007; 139:545.</a></li><li><a class="nounderline abstract_t">Zwaan M, Lorch H, Kulke C, et al. Clinical experience with temporary vena caval filters. J Vasc Interv Radiol 1998; 9:594.</a></li><li><a class="nounderline abstract_t">Köcher M, Krcova V, Cerna M, Prochazka M. Retrievable Günther Tulip Vena Cava Filter in the prevention of pulmonary embolism in patients with acute deep venous thrombosis in perinatal period. Eur J Radiol 2009; 70:165.</a></li><li><a class="nounderline abstract_t">Matsunaga Y, Haba T, Kobayashi M, et al. Evaluation of radiation dose for inferior vena cava filter placement during pregnancy: A comparison of dosimetry and dose calculation software. J Appl Clin Med Phys 2023; 24:e13884.</a></li><li><a class="nounderline abstract_t">Harris SA, Velineni R, Davies AH. Inferior Vena Cava Filters in Pregnancy: A Systematic Review. J Vasc Interv Radiol 2016; 27:354.</a></li><li><a class="nounderline abstract_t">Crosby DA, Ryan K, McEniff N, et al. Retrievable Inferior vena cava filters in pregnancy: Risk versus benefit? Eur J Obstet Gynecol Reprod Biol 2018; 222:25.</a></li><li><a class="nounderline abstract_t">Sensakovic WF, Royall I, Hough M, et al. Fetal Dosimetry at CT: A Primer. Radiographics 2020; 40:1061.</a></li><li><a class="nounderline abstract_t">Maughan BC, Marin M, Han J, et al. Venous Thromboembolism During Pregnancy and the Postpartum Period: Risk Factors, Diagnostic Testing, and Treatment. Obstet Gynecol Surv 2022; 77:433.</a></li><li><a class="nounderline abstract_t">Bistervels IM, Buchmüller A, Tardy B. Inferior vena cava filters in pregnancy: Safe or sorry? Front Cardiovasc Med 2022; 9:1026002.</a></li><li><a class="nounderline abstract_t">Thomas LA, Summers RR, Cardwell MS. Use of Greenfield filters in pregnant women at risk for pulmonary embolism. South Med J 1997; 90:215.</a></li><li><a class="nounderline abstract_t">Milford W, Chadha Y, Lust K. Use of a retrievable inferior vena cava filter in term pregnancy: case report and review of literature. Aust N Z J Obstet Gynaecol 2009; 49:331.</a></li><li><a class="nounderline abstract_t">Jindal N, Gupta V, Kandoria M, Rao R. Venous Thromboembolism in Pregnancy and IVC Filter: A Case Report. J Obstet Gynaecol India 2022; 72:395.</a></li><li><a class="nounderline abstract_t">McConville RM, Kennedy PT, Collins AJ, Ellis PK. Failed retrieval of an inferior vena cava filter during pregnancy because of filter tilt: report of two cases. Cardiovasc Intervent Radiol 2009; 32:174.</a></li><li><a class="nounderline abstract_t">Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995; 50:534.</a></li><li><a class="nounderline abstract_t">Patterson DE, Raviola CA, D'Orazio EA, et al. Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report. J Vasc Surg 1996; 24:1030.</a></li><li><a class="nounderline abstract_t">Herrera S, Comerota AJ, Thakur S, et al. Managing iliofemoral deep venous thrombosis of pregnancy with a strategy of thrombus removal is safe and avoids post-thrombotic morbidity. J Vasc Surg 2014; 59:456.</a></li><li><a class="nounderline abstract_t">Bloom AI, Farkas A, Kalish Y, et al. Pharmacomechanical catheter-directed thrombolysis for pregnancy-related iliofemoral deep vein thrombosis. J Vasc Interv Radiol 2015; 26:992.</a></li><li><a class="nounderline abstract_t">Funakoshi Y, Kato M, Kuratani T, et al. Successful treatment of massive pulmonary embolism in the 38th week of pregnancy. Ann Thorac Surg 2004; 77:694.</a></li><li><a class="nounderline abstract_t">Rodriguez D, Jerjes-Sanchez C, Fonseca S, et al. Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review. J Thromb Thrombolysis 2020; 50:929.</a></li><li><a class="nounderline abstract_t">Martillotti G, Boehlen F, Robert-Ebadi H, et al. Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review. J Thromb Haemost 2017; 15:1942.</a></li><li><a class="nounderline abstract_t">Sousa Gomes M, Guimarães M, Montenegro N. Thrombolysis in pregnancy: a literature review. J Matern Fetal Neonatal Med 2019; 32:2418.</a></li><li><a class="nounderline abstract_t">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014; 311:2414.</a></li><li><a class="nounderline abstract_t">Naoum EE, Chalupka A, Haft J, et al. Extracorporeal Life Support in Pregnancy: A Systematic Review. J Am Heart Assoc 2020; 9:e016072.</a></li><li><a class="nounderline abstract_t">Blondon M, Martinez de Tejada B, Glauser F, et al. Management of high-risk pulmonary embolism in pregnancy. Thromb Res 2021; 204:57.</a></li></ol></div><div id="topicVersionRevision">Topic 1350 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315276" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18987370" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Venous thromboembolic disease and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889451" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary embolism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20436310" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Deep vein thrombosis and pulmonary embolism in pregnancy: diagnosis, complications, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21501137" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : How I manage venous thromboembolism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21921048" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : How I treat pregnancy-related venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thromboembolism in Pregnancy. ACOG 2018</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165544" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482767" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31473594" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598959" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9477044" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : FDA public health advisory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625640" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Spinal and epidural hematoma and low-molecular-weight heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27346676" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266575" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Current concepts of anticoagulant therapy in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519211" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Venous thrombosis during pregnancy: leg and trimester of presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760866" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24524551" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of a thrombotic event after the 6-week postpartum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916101" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684829" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical experience with temporary vena caval filters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242910" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Retrievable Günther Tulip Vena Cava Filter in the prevention of pulmonary embolism in patients with acute deep venous thrombosis in perinatal period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36546565" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of radiation dose for inferior vena cava filter placement during pregnancy: A comparison of dosimetry and dose calculation software.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26746328" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inferior Vena Cava Filters in Pregnancy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29331855" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Retrievable Inferior vena cava filters in pregnancy: Risk versus benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32559149" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fetal Dosimetry at CT: A Primer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35792687" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Venous Thromboembolism During Pregnancy and the Postpartum Period: Risk Factors, Diagnostic Testing, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36419489" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inferior vena cava filters in pregnancy: Safe or sorry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9042175" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Use of Greenfield filters in pregnant women at risk for pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19566571" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of a retrievable inferior vena cava filter in term pregnancy: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36457451" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Venous Thromboembolism in Pregnancy and IVC Filter: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18677532" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Failed retrieval of an inferior vena cava filter during pregnancy because of filter tilt: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566831" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of thrombolytics for the treatment of thromboembolic disease during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8976357" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thrombolytic and endovascular treatment of peripartum iliac vein thrombosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958068" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Managing iliofemoral deep venous thrombosis of pregnancy with a strategy of thrombus removal is safe and avoids post-thrombotic morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899048" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pharmacomechanical catheter-directed thrombolysis for pregnancy-related iliofemoral deep vein thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14759462" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Successful treatment of massive pulmonary embolism in the 38th week of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32347509" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28805341" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29378443" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Thrombolysis in pregnancy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24938564" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32578471" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Extracorporeal Life Support in Pregnancy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146979" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Management of high-risk pulmonary embolism in pregnancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
